Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRX-920 Oral Gel in Advanced Solid Tumors
NCT06143774Phase 1Recruiting
- Sponsor
- TaiRx, Inc.
- Start
- Oct 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TRX-920 in solid tumor (advanced stage), sponsored by TaiRx, Inc. Primary endpoints: Maximum Tolerated Dose at 4 weeks, Recommended Phase 2 Dose at 4 weeks and 1 more. Started Oct 2023; status: recruiting.
02
Drugs
TRX-920
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06143774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06143774.